TB Alternative Assets Ltd. Acquires Shares of 38,996 BioNTech SE (NASDAQ:BNTX)

TB Alternative Assets Ltd. acquired a new stake in BioNTech SE (NASDAQ:BNTX - Free Report) during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm acquired 38,996 shares of the company's stock, valued at approximately $3,551,000. BioNTech makes up about 0.8% of TB Alternative Assets Ltd.'s holdings, making the stock its 27th largest holding.

A number of other large investors also recently made changes to their positions in BNTX. Jones Financial Companies Lllp lifted its position in shares of BioNTech by 110.3% during the fourth quarter. Jones Financial Companies Lllp now owns 469 shares of the company's stock valued at $53,000 after purchasing an additional 246 shares in the last quarter. Quintet Private Bank Europe S.A. lifted its position in shares of BioNTech by 823.5% during the fourth quarter. Quintet Private Bank Europe S.A. now owns 785 shares of the company's stock valued at $88,000 after purchasing an additional 700 shares in the last quarter. Allianz SE bought a new position in shares of BioNTech during the fourth quarter valued at about $90,000. Generali Investments CEE investicni spolecnost a.s. bought a new position in shares of BioNTech during the fourth quarter valued at about $137,000. Finally, AlphaCentric Advisors LLC bought a new position in shares of BioNTech during the fourth quarter valued at about $168,000. 15.52% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of research analysts recently weighed in on BNTX shares. Wall Street Zen raised shares of BioNTech from a "sell" rating to a "hold" rating in a research report on Saturday. Truist Financial reissued a "buy" rating and set a $155.00 price target (up from $151.00) on shares of BioNTech in a research report on Tuesday, June 3rd. Canaccord Genuity Group reissued a "buy" rating and set a $171.44 price target on shares of BioNTech in a research report on Tuesday, March 11th. Leerink Partners set a $112.00 price target on shares of BioNTech in a research report on Monday, June 2nd. Finally, JPMorgan Chase & Co. lowered their price objective on shares of BioNTech from $120.00 to $116.00 and set a "neutral" rating on the stock in a research report on Thursday, May 22nd. Five equities research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has given a strong buy rating to the company's stock. According to data from MarketBeat.com, BioNTech currently has a consensus rating of "Moderate Buy" and a consensus target price of $138.25.

BioNTech Price Performance

BNTX opened at $108.49 on Friday. The company has a market capitalization of $26.08 billion, a price-to-earnings ratio of -51.66 and a beta of 1.29. The company has a quick ratio of 7.21, a current ratio of 7.33 and a debt-to-equity ratio of 0.01. The firm has a 50-day moving average price of $99.26 and a 200-day moving average price of $108.40. BioNTech SE has a twelve month low of $76.53 and a twelve month high of $131.49.

BioNTech (NASDAQ:BNTX - Get Free Report) last posted its earnings results on Monday, March 10th. The company reported $1.08 earnings per share for the quarter, topping the consensus estimate of $0.38 by $0.70. The firm had revenue of $1.19 billion during the quarter, compared to the consensus estimate of $1.24 billion. BioNTech had a negative net margin of 15.16% and a negative return on equity of 2.35%. The company's revenue was down 19.5% on a year-over-year basis. During the same quarter last year, the company earned $1.90 earnings per share. Equities analysts expect that BioNTech SE will post -3.88 EPS for the current year.

BioNTech Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.